NCT02835742View on ClinicalTrials.gov

Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

September 1, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

June 30, 2018

Conditions
Pulmonary Alveolar Proteinosis, Autoimmune
Interventions
DRUG

Sargramostim

DRUG

Placebo

Trial Locations (1)

Unknown

Niigata University Med & Dental Hospital, Niigata

All Listed Sponsors
lead

Niigata University Medical & Dental Hospital

OTHER

NCT02835742 - Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan | Biotech Hunter | Biotech Hunter